Olle Stål

9.9k total citations
183 papers, 7.5k citations indexed

About

Olle Stål is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Olle Stål has authored 183 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 95 papers in Cancer Research and 75 papers in Genetics. Recurrent topics in Olle Stål's work include Breast Cancer Treatment Studies (69 papers), Estrogen and related hormone effects (68 papers) and HER2/EGFR in Cancer Research (36 papers). Olle Stål is often cited by papers focused on Breast Cancer Treatment Studies (69 papers), Estrogen and related hormone effects (68 papers) and HER2/EGFR in Cancer Research (36 papers). Olle Stål collaborates with scholars based in Sweden, United States and United Kingdom. Olle Stål's co-authors include Bo Nordenskjöld, Lambert Skoog, Gizeh Pérez‐Tenorio, Tommy� Fornander, John Carstensen, Sten Wingren, Lars Erik Rutqvist, Mårten Fernö, Göran Landberg and Lisa Rydén and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Olle Stål

182 papers receiving 7.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olle Stål Sweden	49	3.9k	3.4k	2.6k	2.0k	1.2k	183	7.5k
Yasuo Miyoshi Japan	52	3.4k 0.9×	4.6k 1.3×	2.3k 0.9×	1.6k 0.8×	1.0k 0.8×	252	9.3k
C. Kent Osborne United States	42	3.8k 1.0×	2.8k 0.8×	2.4k 0.9×	2.9k 1.5×	1.0k 0.8×	104	7.4k
Janine Salter United Kingdom	41	5.1k 1.3×	2.9k 0.8×	4.8k 1.8×	2.4k 1.2×	1.3k 1.1×	86	8.8k
Allen C. Gao United States	54	2.7k 0.7×	4.4k 1.3×	2.6k 1.0×	839 0.4×	3.5k 2.8×	161	8.4k
Els M.J.J. Berns Netherlands	40	2.4k 0.6×	3.9k 1.1×	2.3k 0.9×	1.1k 0.6×	671 0.5×	87	6.3k
D. Craig Allred United States	32	4.5k 1.2×	2.8k 0.8×	3.4k 1.3×	2.4k 1.2×	931 0.7×	54	7.5k
C. Kent Osborne United States	33	2.9k 0.8×	2.2k 0.6×	2.1k 0.8×	1.8k 0.9×	743 0.6×	82	5.6k
Anne F. Schott United States	32	4.4k 1.1×	2.4k 0.7×	2.5k 1.0×	489 0.2×	898 0.7×	92	7.0k
Grazia Arpino Italy	37	4.2k 1.1×	1.7k 0.5×	2.8k 1.1×	1.6k 0.8×	1.6k 1.3×	157	6.7k
Ju‐Seog Lee United States	61	3.7k 0.9×	7.9k 2.3×	3.9k 1.5×	559 0.3×	2.2k 1.7×	218	13.3k

Countries citing papers authored by Olle Stål

Since Specialization

Citations

This map shows the geographic impact of Olle Stål's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olle Stål with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olle Stål more than expected).

Fields of papers citing papers by Olle Stål

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olle Stål. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olle Stål. The network helps show where Olle Stål may publish in the future.

Co-authorship network of co-authors of Olle Stål

This figure shows the co-authorship network connecting the top 25 collaborators of Olle Stål. A scholar is included among the top collaborators of Olle Stål based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olle Stål. Olle Stål is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Salunga, Ranelle, Wilma E. Mesker, Linda de Munck, et al.. (2025). Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index. Clinical Cancer Research. 31(11). 2222–2229. 1 indexed citations

Nordenskjöld, Anna, Helena Fohlin, Johan Rosell, et al.. (2023). Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. The Breast. 71. 63–68. 2 indexed citations

Danielsson, Oscar, Gizeh Pérez‐Tenorio, Anna Nordenskjöld, et al.. (2023). Abstract P3-05-03: Long-term survival and intra-tumor heterogeneity of progesterone receptor expression in estrogen receptor-positive/progesterone receptor-positive premenopausal women with breast cancer. Cancer Research. 83(5_Supplement). P3–5. 1 indexed citations

Eliáš, Daniel, Carla L. Alves, Martin V. Bennetzen, et al.. (2021). MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. npj Breast Cancer. 7(1). 2–2. 11 indexed citations

Fornander, Tommy�, et al.. (2016). Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer. British Journal of Cancer. 114(3). 248–255. 46 indexed citations

Manna, Subrata, Josefine Bostner, Yang Sun, et al.. (2015). ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research. 22(6). 1421–1431. 51 indexed citations

Busch, Susann, Andrew H. Sims, Olle Stål, Mårten Fernö, & Göran Landberg. (2015). Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance. Cancer Research. 75(7). 1457–1469. 22 indexed citations

Gabrielson, Marike, et al.. (2015). Mitochondrial regulation of cell cycle progression through SLC25A43. Biochemical and Biophysical Research Communications. 469(4). 1090–1096. 9 indexed citations

Bostner, Josefine, Elin Karlsson, Cecilia Bivik, et al.. (2015). S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. Endocrine Related Cancer. 22(3). 331–343. 24 indexed citations

10.

Zhang, Yi, Catherine A. Schnabel, Brock E. Schroeder, et al.. (2013). Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. Clinical Cancer Research. 19(15). 4196–4205. 163 indexed citations

11.

Lundgren, Katja, Nicholas P. Tobin, Sophie Lehn, et al.. (2011). Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer. Journal of Molecular Diagnostics. 13(3). 340–351. 23 indexed citations

12.

Bostner, Josefine, Lambert Skoog, Tommy� Fornander, Bo Nordenskjöld, & Olle Stål. (2010). Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer. Clinical Cancer Research. 16(5). 1624–1633. 48 indexed citations

13.

Kok, Marleen, Wilbert Zwart, Caroline Holm, et al.. (2010). PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Research and Treatment. 125(1). 1–12. 46 indexed citations

14.

Miller, Todd W., Marianela Pérez-Torres, Archana Narasanna, et al.. (2009). Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. Cancer Research. 69(10). 4192–4201. 141 indexed citations

15.

Jansson, Agneta, Cecilia Gunnarsson, & Olle Stål. (2006). Proliferative responses to altered 17β-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocrine Related Cancer. 13(3). 875–884. 17 indexed citations

16.

Stål, Olle, Gizeh Pérez‐Tenorio, Birgit Olsson, et al.. (2003). Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Research. 5(2). R37–44. 140 indexed citations

17.

Bagwell, C. Bruce, Clark Gm, F. Spyratos, et al.. (2001). Multivariate analyses of flow cytometric S-phase and ploidy as node-negative breast cancer prognostic factors : an international and multi-center study. Breast Cancer Research and Treatment. 69(3). 260–260. 1 indexed citations

18.

Stål, Olle, Marie Stenmark Askmalm, Sten Wingren, et al.. (1995). P53 Expression and the Result of Adjuvant Therapy of Breast Cancer. Acta Oncologica. 34(6). 767–770. 32 indexed citations

19.

Stål, Olle, Lambert Skoog, Lars Erik Rutqvist, et al.. (1994). S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. British Journal of Cancer. 70(6). 1258–1262. 49 indexed citations

20.

Stål, Olle, et al.. (1994). Simultaneous analysis of c‐erbB‐2 expression and DNA content in breast cancer using flow cytometry. Cytometry. 16(2). 160–168. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact